When employing the developed IP-HR-PRM-MS method, the levels of the three investigated tryptic LAMP2 peptides were found to be increased in subjects with an AD core biomarker profile (see “CSF samples” in “Methods” section) compared with subjects with a control biomarker profile. This evidence concerns the gene LAMP2 and Alzheimer disease.